$NTRA

Fesko John sold $440K of NTRA

Fesko John (PRESIDENT, CHIEF BUS. OFFICER) sold 1,713 shares of Natera, Inc. (NTRA) at an average of $257.00 ($254.07–$260.49, $0.44M total) across 2 trades over 2026-07-27 to 2026-07-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Fesko John
Published Jul 30, 2026, 1:35 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 30, 2026, 2:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$NTRA
Neutral
high confidence
Mentioned
$NTRA
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The disclosure provides transparency on executive share sales but does not introduce new company-specific catalysts like earnings, guidance, trials, deals, or regulatory actions.

02

Market read

For NTRA, this is primarily a sentiment datapoint rather than a fundamental driver.

03

What to watch

Traders may over-weight insider selling; the key incremental data here is only the disclosed sale size and timing, not any change in guidance or business performance.

Relevance 3/10Novelty 3/10Timing: after-hours SEC Form 4 filing dated 2026-07-29 for sales on 2026-07-27 to 2026-07-28

Background

The article is an SEC Form 4 insider transaction disclosure for Natera, Inc.

Company-level read

Ticker impact

$NTRANeutralHigh confidence
Context

Natera insider Form 4 shows President/COO Fesko John sold about 1,713 shares for roughly $440K under a 10b5-1 plan.

Expected impact

Likely minimal, with any effect confined to short-term sentiment rather than a fundamental repricing.

Evidence & confidence

The filing is a disclosed insider transaction, but it is explicitly pre-arranged under Rule 10b5-1 and does not include new operating, financial, or regulatory information.

Market effects

No clear read-across to the broader biotech/diagnostics sector from a single routine 10b5-1 sale.

None.

None.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect liquidity planning rather than bearish expectations.

Key entities

  • Natera, Inc.

    Company whose insider transaction is disclosed on Form 4.

  • Fesko John

    President and Chief Business Officer who sold shares under a 10b5-1 plan.

Related articles

$NTRAHighAI 9/10

Natera Stock Jumps After Q2 Beat And Guidance Hike

Natera Inc. (NTRA) shares rose about 20.9% after Q2 results and guidance. Q2 revenue was $752.8M versus $661.2M consensus, with a Q2 loss of $0.47 per share versus $0.49 expected. Full-year 2026 revenue guidance was raised to $2.85B to $2.91B. The Signatera test was submitted to Japan’s PMDA for muscle-invasive bladder cancer.

$NTRAMedAI 8/10

NTRA Soars As Natera Beats Q2 And Lifts 2026 Outlook

Natera (NTRA) shares rose about 21% after the company reported Q2 2026 revenue of $752.8M versus ~$661.2M consensus and a $0.47 per-share loss versus a ~$0.49 loss estimate. Natera lifted FY2026 revenue guidance to $2.85B to $2.91B. The article cites gross margin around 65% and notes free cash flow about $18M.

$NTRAHighAI 9/10

NTRA Stock Soars After Earnings Beat And Raised 2026 Outlook

Natera Inc. (NTRA) shares rose after Q2 results and a raised 2026 outlook. According to the company, Q2 revenue was $752.8M vs $661.2M consensus, with a Q2 loss of $0.47 per share vs $0.49 expected. Full-year 2026 revenue guidance was lifted to $2.85B–$2.91B. The company also submitted its Signatera MRD test to Japan’s PMDA for muscle-invasive bladder cancer.

$NTRAMedAI 8/10

Natera Stock Hits 52-Week High - Here's Why - Natera (NASDAQ:NTRA)

Natera (NTRA) reported Q2 adjusted loss of 47 cents per share, better than the 51-cent consensus. Revenue rose 37.7% to $752.8M, above $660.7M estimates, driven by higher test volumes and improved pricing. Oncology tests grew 56% YoY and the company processed 1.04M tests. Fiscal 2026 revenue guidance was raised to $2.85B-$2.91B. Analysts lifted price targets; shares hit a 52-week high.

$NTRAMedAI 8/10

These Two Biotech Stocks Hit Fresh 52-Week Highs Today – NTRA Clocks Best Day In Nearly 20 Months

Natera (NTRA) shares hit fresh 52-week highs after Q2 revenue of $752.8M beat estimates of $661.3M and the company raised FY2026 revenue guidance to $2.85B-$2.91B. BTIG lifted its NTRA price target to $320 and JPMorgan to $360. Halozyme (HALO) also reached a 52-week high after Q2 revenue rose 48% to $481M; Leerink upgraded to Outperform and set $110.